111, Inc.
111, Inc. is a U.S.-listed healthcare commerce and services platform organized around China’s pharmaceutical supply chain. It operates online retail pharmacy, internet hospital, pharmacy-sourcing, and digital commercialization businesses that connect consumers, pharmacies, and pharmaceutical manufacturers through its 1 Pharmacy, 1 Clinic, and 1 Medicine platforms.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDirect-to-consumer pharmaceutical sales and related healthcare products through the 1 Pharmacy channel.
Platform and service fees generated from marketplace, commercialization, and partner services.
Online consultation, e-prescription, and patient management services delivered through 1 Clinic.
Pharmacy sourcing, product distribution, and virtual pharmacy network services through 1 Medicine.
Promotional, data, and brand-building services for pharmaceutical partners and pharmacies.
Customers
111 sells to both consumers seeking prescription and OTC pharmacy access and to offline pharmacies that use its sourcing and cloud-based tools. It also serves pharmaceutical manufacturers and strategic partners that buy commercialization, marketing, and distribution access across its platform. The business is built around demand from China’s pharmacy and healthcare ecosystem rather than from a single end market.
Buy pharmaceuticals and online healthcare services through 1 Pharmacy and 1 Clinic for convenience and access.
Buy sourcing, cloud tools, and virtual pharmacy network services to improve procurement and customer service.
Buy commercialization, digital marketing, and distribution access to reach pharmacies and end customers.
Buy promoted products and sourcing support to expand assortment and improve sell-through.
Buy patient education, data analytics, and pricing monitoring services.
Strategy
111 is moving toward a more asset-light, platform-oriented model that relies more on service revenue and less on balance-sheet-heavy fulfillment. It is also broadening SKU coverage, partner relationships, and digital commercialization tools to deepen pharmacy penetration and improve monetization across the supply chain.
Reduces fulfillment intensity and shifts the model toward service and commission revenue.
More SKUs and distribution rights improve pharmacy reach and strengthen monetization.
Digital marketing and analytics help pharmaceutical partners reach downstream buyers more effectively.
Geography
The company is centered in China, where its online pharmacy, internet hospital, and pharmacy-network services are deployed. It is headquartered in the United States for listing purposes, but its commercial activity, customer base, and operating footprint are primarily in China. That geography ties the business closely to Chinese healthcare regulation, pharmacy distribution practices, and digital health adoption.
Risks
111’s business depends on Chinese healthcare regulation, pharmacy channel economics, and continued participation by pharmacies, consumers, and drug makers on its platform. Its transition to a platform model also depends on execution, while its balance sheet and redemption obligations create additional financial risk if cash generation is uneven.
- China healthcare and online pharmacy regulationImpact: HighLikelihood: High
The core business operates in Chinese digital health and drug commerce, which is policy-sensitive.
Exposure - Redemption obligation and liquidity strainImpact: HighLikelihood: High
Investor redemption liabilities and cash outflows can reduce financial flexibility.
Exposure: 1 Pharmacy Technology redemption arrangements
- Platform transition executionImpact: HighLikelihood: Medium
The company is shifting revenue mix and operating model, which can disrupt growth and service delivery if not managed well.
Exposure - Competitive pressure in online healthcareImpact: MediumLikelihood: High
The business competes on access, pricing, and platform reach in a crowded digital pharmacy market.
Exposure - Partner concentration and supply chain dependenceImpact: MediumLikelihood: Medium
Distribution rights and promotional performance rely on pharmaceutical company cooperation and pharmacy demand.
Exposure
Accounting
Judgemental itemsProduct sales, marketplace services, and healthcare services may be recognized differently and affect comparability.
Impact: Mix shift can change reported growth rates and margins.
Investor redemption rights create substantial obligations and liability estimates.
Impact: Affects current liabilities, liquidity, and loss presentation.
Material non-cash expense is excluded from non-GAAP measures.
Impact: Can widen the gap between GAAP and adjusted results.
The move to a warehouse partnership model changes how fulfillment costs and assets are recognized.
Impact: Can alter cost of revenue, operating expense, and working capital.
Similar listed companies
Publicly listed companies with a comparable business focus.
Waterdrop Inc.
WDH · Insurance Agents, Brokers & Service
POMDOCTOR Ltd
POM · Retail-Miscellaneous Retail
POMDOCTOR Ltd is a China-based digital healthcare company built around an internet hospital platform, physician network, and pharmaceutical supply chain operations.
Longduoduo Co Ltd
LDDD · Services-Health Services
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct…
Kun Peng International Ltd.
KPEA · Services-Educational Services
Zhongchao Inc.
ZCMD · Services-Educational Services
GoodRx Holdings, Inc.
GDRX · Services-Computer Processing & Data Preparation
Last updated: 28/09/2026